Sugi Predict

Sugi Predict / Targets / ASAH1

ASAH1

Acid ceramidase · Q13510 · ASAH1 on Sugi Atlas →

19,823 patent compounds predicted against ASAH1, 11,420 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL426726 SCHEMBL426726 1.00 14/20
SCHEMBL162357 SCHEMBL162357 0.51 10/20
SCHEMBL205803 SCHEMBL205803 0.53 9/20
SCHEMBL424357 SCHEMBL424357 1.00 8/20
SCHEMBL1324358 SCHEMBL1324358 0.60 8/20
SCHEMBL159671 SCHEMBL159671 0.47 8/20
SCHEMBL675169 SCHEMBL675169 0.62 7/20
Benomyl Benomyl (SCHEMBL15681) 0.60 7/20
SCHEMBL205087 SCHEMBL205087 0.52 7/20
Benomyl Benomyl (SCHEMBL542435) 0.47 7/20
SCHEMBL202740 SCHEMBL202740 0.46 7/20
SCHEMBL116004 SCHEMBL116004 0.57 6/20
SCHEMBL250172 SCHEMBL250172 0.57 6/20
SCHEMBL669244 SCHEMBL669244 0.56 6/20
SCHEMBL669245 SCHEMBL669245 0.56 6/20
SCHEMBL669246 SCHEMBL669246 0.56 6/20
SCHEMBL202633 SCHEMBL202633 0.53 6/20
SCHEMBL202634 SCHEMBL202634 0.53 6/20
SCHEMBL205086 SCHEMBL205086 0.53 6/20
SCHEMBL427076 SCHEMBL427076 0.49 6/20

Clinical trials — most relevant to ASAH1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. PHASE4COMPLETED
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis PHASE4COMPLETED
Bezafibrate Trial in CPT2 Deficiency PHASE3UNKNOWN
Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo PHASE2UNKNOWN
Hereditary Sensory Neuropathy Serine Trial PHASE2UNKNOWN
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients PHASE1COMPLETED
Biomarker for Farber Disease (BioFarber) nanWITHDRAWN
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital nanNOT_YET_RECRUITING
Farber Disease Natural History Study nanCOMPLETED
Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease nanNOT_YET_RECRUITING
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children nanNOT_YET_RECRUITING
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease nanCOMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Miglustat on Gaucher Disease Type IIIB nanUNKNOWN
Registry Gangliosidoses nanUNKNOWN
Biomarkers Of Lung InVolvement In ASMD nanUNKNOWN
Omics Gaucher Study: Multiomic Approach nanACTIVE_NOT_RECRUITING
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Genetic and Metabolic Disease in Children nanRECRUITING
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders nanUNKNOWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia nanUNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma nanRECRUITING
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ASAH1 binder may also engage these)

ProteinNameSimilarity
Q9WV54 — 1.000 Q9WV54 →
A0A0P6JG37 — 1.000 A0A0P6JG37 →
A0A383ZFX3 — 1.000 A0A383ZFX3 →
Q17QB3 — 1.000 Q17QB3 →
A5A6P2 — 1.000 A5A6P2 →
Q60HH4 — 0.999 Q60HH4 →
Q6P7S1 — 0.999 Q6P7S1 →
Q9GUI1 — 0.995 Q9GUI1 →
Q09551 — 0.989 Q09551 →
O45686 — 0.989 O45686 →
Q9XWV2 — 0.985 Q9XWV2 →
Q9D7V9 — 0.985 Q9D7V9 →
Q5KTC7 — 0.984 Q5KTC7 →
O62146 — 0.982 O62146 →
F8J2D3 — 0.981 F8J2D3 →
Q9BL07 — 0.979 Q9BL07 →
F8S101 — 0.978 F8S101 →
NAAA N-acylethanolamine-hydrolyzing acid amidase 0.978 landscape →
Q6TGQ8 — 0.977 Q6TGQ8 →
Q9GL30 — 0.977 Q9GL30 →
ACE2 Angiotensin-converting enzyme 2 0.976 landscape →
Q90W54 — 0.976 Q90W54 →
Q5UR76 — 0.976 Q5UR76 →
Q4JHE2 — 0.976 Q4JHE2 →
Q5U2V4 — 0.976 Q5U2V4 →
P0CC17 — 0.976 P0CC17 →
G1T7U7 — 0.976 G1T7U7 →
ERMP1 Endoplasmic reticulum metallopeptidase 1 0.975 landscape →
Q5R7P4 — 0.975 Q5R7P4 →
Q9GV16 — 0.975 Q9GV16 →